Results 31 to 40 of about 9,997 (164)
Movement Disorders Clinical Practice, EarlyView.Abstract Background Progressive supranuclear palsy (PSP) is a neurodegenerative disorder characterized by motor, oculomotor and cognitive impairments. Yet disentangling cognitive deficits from motor and oculomotor dysfunction remains a diagnostic and methodological challenge.
Indira Garcia‐Cordero +12 more
wiley +1 more source
Rivastigmine prevents injury induced by ischemia and reperfusion in rat liver [PDF]
Acta Cirúrgica Brasileira, 2018 Purpose: To evaluate whether pre-treatment with rivastigmine is able to attenuate the I/R induced lesions in rat liver. Methods: SHAM animals or those submitted to I/R, non-treated or pre-treated with rivastigminine (2mg/kg) either 50 or 15 minutes ...
Agnaldo Bruno Chies +6 more
doaj +1 more source
Biomedicines, 2022 Alzheimer’s disease (AD) is the most serious and prevalent neurodegenerative disorder still without cure. Since its aetiology is diverse, recent research on anti-AD drugs has been focused on multi-target compounds.
David Vicente-Zurdo +9 more
doaj +1 more source
Apathy in Lewy Body Disorders: A Position Paper
Movement Disorders, EarlyView.Abstract Apathy is one of the most prevalent and disabling non‐motor symptoms in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), collectively referred to as Lewy body disorders (LBDs). It is associated with reduced quality of life, accelerated cognitive decline, increased caregiver burden, and poorer functional outcomes, yet remains ...
Jaime Kulisevsky +12 more
wiley +1 more source
EFFECTS OF 6-MONTHS TREATMENT WITH DONEPEZIL AND RIVASTIGMIN ON RESULTS OF NEUROPSYCHOLOGICAL TESTS OF MMSE, NPI, CLOCK AND BENDER IN PATIENTS WITH ALZHEIMER'S DISEASE [PDF]
Acta Medica Iranica, 2008 Alzheimer's disease is the most common degenerative disease of brain. Nowadays, the most common treatment being used to slow down disease progression, include Donepezil , Rivastigmine and Galantamine, which all of them act as inhibitors of acetyl ...
R. Abolfazli, S. Ghazanshahi M. Nazeman
doaj
Cost-effectiveness analysis of the treatment of mild and moderate Alzheimer’s disease in Brazil
Brazilian Journal of Psychiatry, 2018 Objective: To perform a cost-effectiveness analysis of donepezil and rivastigmine therapy for mild and moderate Alzheimer’s disease (AD) from the perspective of the Brazilian Unified Health System.
Luciana R. da Silva +5 more
doaj +1 more source
Pharmaceutics, 2022 Cerium oxide nanoparticles (CNPs), owing to their antioxidant property, have recently emerged as therapeutic candidate for Alzheimer’s disease (AD). However, intravenous CNPs are limited due to their poor physicochemical properties, rapid blood clearance
Syed Mohammad Danish +8 more
doaj +1 more source
Journal of Sleep Research, Volume 34, Issue 2, April 2025.Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont +5 more
wiley +1 more source
Psychiatry and Clinical Neurosciences, EarlyView.Aim To determine the smallest worthwhile difference (SWD) for lecanemab, a disease‐modifying drug for Alzheimer's disease (AD), among the general Japanese population using a benefit‐harm trade‐off method. Methods We conducted an online survey with 658 participants to evaluate their preferences for the treatment effect of lecanemab, given its associated
Aran Tajika +5 more
wiley +1 more source
Food Frontiers, Volume 7, Issue 5, September 2026.Ketogenic diet (KD) confers neuroprotection in Alzheimer's disease by inhibiting microglial HDAC3. This simultaneously enhances Aβ clearance via TREM2‐mediated phagocytosis and AMPK–ULK1‐driven autophagy, while suppressing NLRP3 inflammasome activation, ultimately attenuating Aβ/tau pathology and neuronal damage. ABSTRACT Growing evidence suggests that
Mingxiao Zheng +7 more
wiley +1 more source